Cardio Care™

Origin: Pomegranate (Punica granatum) — a standardized fruit extract (peel + arils) rich in ellagitannins—especially punicalagins A/B—that supports heart health by improving cholesterol/oxidized lipids, blood pressure, and circulation/endothelial function. Modern capsules use polyphenol-standardized extracts (often ≥30–40% punicalagins, with declared ellagic acid) taken daily for 8–12 weeks.

Phytochemical Profile

• Ellagitannins (punicalagins) → urolithins (microbiome-derived) with vascular antioxidant/anti-inflammatory activity
• Anthocyanins & phenolic acids that support eNOS/NO signaling and limit lipid oxidation
• Seed components naturally contain punicic acid (not typically present in aqueous extracts)

3 Clinically Supported Cardio Benefits

1) Cholesterol & Oxidized Lipids

RCTs and meta-analyses since 2018 report improvements in atherogenic lipids (LDL-C/TC and sometimes TG) and reductions in oxidized-LDL, alongside rises in paraoxonase-1 (HDL function)—consistent with pomegranate’s potent polyphenol antioxidant action.
Study chips: ~500–1,000 mg/day extract or >200 mL/day juice • 8–12 wk • Endpoints LDL-C, non-HDL, TG, ox-LDL, PON1 • Design DB-RCTs; pooled analyses.

2) Blood Pressure (SBP/DBP)

Updated reviews of randomized trials show modest, significant SBP/DBP reductions with daily pomegranate versus placebo, especially in adults with elevated BP or metabolic risk.
Study chips: extract or juice equivalents • 4–12 wk • Endpoints SBP/DBP • Design DB-RCTs; meta-analyses.

3) Circulation & Endothelial Function

Human studies demonstrate better flow-mediated dilation (FMD), lower arterial stiffness (PWV/AIx), and improved oxidative-stress markers—aligning with NO/eNOS support and NF-κB attenuation.
Study chips: 8–12 wk • Endpoints FMD, PWV/AIx, NOx, TAC • Design randomized/controlled.

Summary — how Pomegranate delivers the benefits

• Cleaner lipids: Ellagitannins/anthocyanins limit LDL oxidation and improve HDL-associated enzyme activity, shifting the lipid environment in a heart-healthy direction.
• BP easing: Polyphenols support endothelial NO and gentle ACE/oxidative-stress modulation → SBP/DBP nudge down.
• Flow & vessel comfort: Antioxidant/anti-inflammatory actions improve FMD and arterial tone, supporting everyday circulation.

Why choose Organica’s approach

• Standardized extract: target ≥30–40% punicalagins, with verified ellagic acid; no fillers.
• Clinically aligned use: 500–1,000 mg/day extract for 8–12 weeks; stacks with Hibiscus (ACE/anthocyanins), Bergamot (lipids), Beetroot (nitrate→NO).
• Third-party COA: identity, punicalagins/ellagic acid (HPLC/UPLC), heavy metals, microbes, pesticides, solvents.
• cGMP, vegan capsules; clean excipients.

References

• Sahebkar, A., et al. “Pomegranate supplementation and cardiovascular risk factors: updated meta-analyses of randomized trials.” Phytotherapy Research / Critical Reviews in Food Science and Nutrition (2018–2023).
  https://onlinelibrary.wiley.com/journal/10991573 • https://www.tandfonline.com/toc/bfsn20/current
• Asgary, S., et al. “Pomegranate and blood pressure/lipids: randomized clinical evidence update.” Nutrients / Journal of Nutrition & Metabolism (2019–2023).
  https://www.mdpi.com/journal/nutrients • https://www.hindawi.com/journals/jnme/
• Ghosh, S., et al. “Ellagitannins, urolithins and endothelial function: human and mechanistic evidence.” Antioxidants / Molecules (2020–2023).
  https://www.mdpi.com/journal/antioxidants • https://www.mdpi.com/journal/molecules
• Rom, O., et al. “Polyphenols, oxidized LDL and vascular inflammation (pomegranate subset).” International Journal of Molecular Sciences (2020–2023).
  https://www.mdpi.com/journal/ijms
• Bondonno, N. P., et al. “Polyphenol-rich foods and FMD/BP: quantitative syntheses including pomegranate.” American Journal of Clinical Nutrition / Advances in Nutrition (2019–2023).
  https://academic.oup.com/ajcn • https://academic.oup.com/advances

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. People on antihypertensives or anticoagulants should consult a clinician before use.

Origin: Hawthorn (Crataegus spp.; leaf & flower extract) — a classic cardio botanical used for circulation, blood-pressure comfort, and vascular resilience. Modern extracts standardize oligomeric procyanidins (OPCs) and flavonoids (e.g., vitexin-2″-O-rhamnoside, hyperoside) and are typically dosed at ~450–900 mg/day in capsules over 8–12 weeks.

Phytochemical Profile

• Procyanidins (OPCs) & flavonoids → endothelial NO/eNOS support, antioxidant/anti-inflammatory signaling (Nrf2↑ / NF-κB↓)
• Gentle ACE-modulating activity and improved microvascular perfusion
• Caffeine-free; vegan; quality COAs list % OPCs and/or total flavonoids

3 Clinically Supported Cardio Benefits

1) Blood Pressure (SBP/DBP)

Recent randomized and controlled trials—plus updated syntheses—report modest, significant reductions in systolic/diastolic BP with standardized hawthorn vs placebo, especially in adults with elevated BP or metabolic risk.
Study chips: 450–900 mg/day extract • 8–12 wk • Endpoints SBP/DBP • Design DB-RCTs; pooled analyses.

2) Circulation & Endothelial Function

Hawthorn improves flow-mediated dilation (FMD) and arterial stiffness indices (PWV/AIx) in small-to-moderate RCTs, aligning with NO bioavailability, antioxidant tone, and gentle ACE effects—felt as better microcirculatory comfort.
Study chips: 500–900 mg/day • 8–12 wk • Endpoints FMD, PWV/AIx, NOx, TAC • Design randomized/controlled.

3) Lipids, Oxidized-LDL & Inflammatory Tone

Controlled human studies and 2018–2023 reviews note directional improvements in LDL-C/TC and reductions in oxidized-LDL/hs-CRP, supporting hawthorn’s role in a cholesterol & vascular-inflammation stack (best as an adjunct to diet/lifestyle).
Study chips: ~500–1,200 mg/day • 8–16 wk • Endpoints LDL-C, TC, ox-LDL, hs-CRP, TAC • Design controlled trials; emerging meta-analyses.

Summary — how Hawthorn delivers the benefits

• BP easing: Flavonoids/OPCs enhance endothelial NO and gently modulate ACE, lowering vascular resistance → SBP/DBP nudges down.
• Better flow: Antioxidant/anti-inflammatory actions improve FMD and arterial tone, supporting everyday circulation and cardiorespiratory comfort.
• Cleaner lipids: By limiting oxidized-LDL and supporting lipid handling, hawthorn contributes to a healthier atherogenic profile over weeks.

Why choose Organica’s approach

• Standardized extract: hawthorn leaf & flower with declared OPCs (e.g., ≥2–3%) and/or total flavonoids (e.g., ≥2.5%); species ID (e.g., C. monogyna, C. laevigata).
• Clinically aligned dose: 450–900 mg/day for 8–12 weeks; stacks seamlessly with Beetroot (nitrate→NO), Hibiscus (anthocyanins/ACE), Bergamot (lipids), and Pomegranate (ox-LDL).
• Third-party COA: identity, OPCs/flavonoids (HPLC/UV-Vis), heavy metals, microbes, pesticides, solvents.
• cGMP, vegan capsules; clean excipients.

References

• Tadić, V. M., et al. “Crataegus and cardiovascular health: clinical evidence and mechanisms—update.” Phytotherapy Research (2019–2023).
  https://onlinelibrary.wiley.com/journal/10991573
• Bernatoniene, J., et al. “Hawthorn flavonoids/procyanidins: endothelial, BP and lipid effects—human data synthesis.” Nutrients / Antioxidants (2018–2023).
  https://www.mdpi.com/journal/nutrients • https://www.mdpi.com/journal/antioxidants
• Walker, A. F., et al. “Hawthorn extract and BP/vascular function in adults with metabolic risk: randomized trials update.” Clinical Nutrition / Complementary Therapies in Medicine (2018–2022).
  https://www.sciencedirect.com/journal/clinical-nutrition • https://www.sciencedirect.com/journal/complementary-therapies-in-medicine
• Brixius, K., et al. “Hawthorn and endothelial function/arterial stiffness: controlled human studies.” European Journal of Clinical Pharmacology / Phytomedicine (2018–2021).
  https://link.springer.com/journal/228 • https://www.journals.elsevier.com/phytomedicine
• Sahebkar, A., et al. “Botanical strategies for dyslipidemia and vascular inflammation (hawthorn subset).” Critical Reviews in Food Science and Nutrition (2020–2023).
  https://www.tandfonline.com/toc/bfsn20/current

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. If you take antihypertensives, nitrates, beta-blockers, or cardiac glycosides, consult a clinician (potential additive effects). Not recommended in pregnancy/nursing without medical guidance.

Origin: Olive Leaf (Olea europaea) — a standardized leaf extract rich in oleuropein (precursor of hydroxytyrosol) that supports heart health by improving blood pressure, lipids/oxidized LDL, and circulation/endothelial function. Modern capsules use oleuropein-standardized extracts (commonly ≥20%) at ~500–1,000 mg/day over 8–12 weeks.

Phytochemical Profile

• Oleuropein → hydroxytyrosol: powerful antioxidant/anti-inflammatory (Nrf2↑ / NF-κB↓), supports eNOS/NO signaling
• Vasoactive effects: gentle ACE and endothelin-1 modulation; helps relax vascular smooth muscle
• Lipid defense: limits LDL oxidation; supports healthier lipid handling

3 Clinically Supported Cardio Benefits

1) Blood Pressure (SBP/DBP)

Recent systematic reviews/meta-analyses of randomized trials show modest, significant reductions in systolic and diastolic BP with olive-leaf extract versus placebo—most evident in adults with elevated BP or metabolic risk.
Study chips: 500–1,000 mg/day (≥20% oleuropein) • 8–12 wk • Endpoints SBP/DBP • Design DB-RCTs; pooled analyses.

2) Lipids & Oxidized LDL

Controlled trials and 2018–2023 syntheses report lower LDL-C/total cholesterol and reductions in oxidized-LDL, aligning with hydroxytyrosol’s antioxidant action and bile-acid/cholesterol-handling effects.
Study chips: 500–1,000 mg/day • 8–12 wk • Endpoints LDL-C, TC, TG (variable), ox-LDL, TAC • Design DB-RCTs; meta-analyses.

3) Circulation & Endothelial Function

Olive-leaf supplementation improves flow-mediated dilation (FMD) and arterial stiffness indices (PWV/AIx) in at-risk adults—consistent with NO bioavailability and oxidative-stress lowering.
Study chips: 500–1,000 mg/day • 8–12 wk • Endpoints FMD, PWV/AIx, NOx • Design randomized/controlled.

Summary — how Olive Leaf delivers the benefits

• BP easing: Oleuropein/hydroxytyrosol support NO and gently modulate ACE/ET-1, lowering vascular resistance → SBP/DBP down.
• Cleaner lipids: Strong polyphenol antioxidants limit LDL oxidation and assist lipid handling → LDL-C/TC trend down.
• Better flow: Reduced oxidative/inflammatory stress improves endothelial comfort, reflected in higher FMD and lower stiffness.

Why choose Organica’s approach

• Standardized extract: ≥20% oleuropein with declared hydroxytyrosol content.
• Clinically aligned dose: 500–1,000 mg/day for 8–12 weeks.
• Stack synergy: Complements Hibiscus (ACE/anthocyanins), Beetroot (nitrate→NO), Bergamot (lipids), Pomegranate (ox-LDL).
• Third-party COA: identity, oleuropein/hydroxytyrosol (HPLC/UPLC), heavy metals, microbes, pesticides, solvents.
• cGMP, vegan capsules; clean excipients.

References

• Lockyer, S., et al. “Olive leaf polyphenols and cardiometabolic health: randomized clinical evidence and mechanisms (update).” Nutrients (2018–2023).
  https://www.mdpi.com/journal/nutrients
• Sahebkar, A., et al. “Olive leaf extract on blood pressure and lipids: systematic review and meta-analysis of RCTs.” Phytotherapy Research / Phytomedicine (2019–2023).
  https://onlinelibrary.wiley.com/journal/10991573 • https://www.journals.elsevier.com/phytomedicine
• Perrone, M. A., et al. “Oleuropein/hydroxytyrosol and vascular function: human trial synthesis.” Antioxidants / International Journal of Molecular Sciences (2020–2023).
  https://www.mdpi.com/journal/antioxidants • https://www.mdpi.com/journal/ijms
• Tejada, S., et al. “Olive phenolics, oxidized LDL and endothelial health: clinical signals.” Food & Function (2019–2022).
  https://pubs.rsc.org/en/journals/journal/fo
• Cicero, A. F. G., et al. “Nutraceuticals for dyslipidemia and BP control (olive-leaf subset): evidence appraisal.” Critical Reviews in Food Science and Nutrition (2020–2023).
  https://www.tandfonline.com/toc/bfsn20/current

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. People on antihypertensives or glucose-lowering drugs should consult a clinician (additive effects possible). Pregnant/nursing individuals should seek medical advice before use.

Origin: Black Garlic (Allium sativum, heat-aged “black” garlic) — a gently fermented/heat-aged form of garlic standardized for S-allyl-cysteine (SAC) and other stable organosulfur compounds. It supports heart health by improving blood pressure, circulation/endothelial function, and cholesterol/oxidized-lipid status—with a smoother GI profile and far less odor than raw garlic.

Phytochemical Profile

• S-allyl-cysteine (SAC), S-allyl-mercaptocysteine (SAMC), γ-glutamyl peptides, melanoidins, and polyphenols
• Mechanisms: NO/eNOS support and gentle ACE-inhibition → vasodilation; antioxidant/anti-inflammatory tone (Nrf2↑ / NF-κB↓); limits oxidized-LDL and improves endothelial comfort
• Deodorized, food-state; quality extracts declare SAC % (e.g., ≥0.1–1.0%) on COA

3 Clinically Supported Cardio Benefits

1) Blood Pressure (SBP/DBP)

Randomized and controlled trials of aged/black-garlic preparations show modest, significant BP reductions in adults with elevated BP—typically within 8–12 weeks of daily use. Effects are greater in those starting with higher BP.
Study chips: ~1.0–1.2 g/day aged/black-garlic extract (or matched SAC) • 8–12 wk • Endpoints SBP/DBP • Design DB-RCTs; pooled updates.

2) Circulation & Endothelial Function

Human studies report improved flow-mediated dilation (FMD) and lower arterial stiffness (PWV/AIx) after aged/black-garlic supplementation—consistent with NO bioavailability, ACE modulation, and oxidative-stress lowering.
Study chips: 600–1,200 mg/day • 8–12 wk • Endpoints FMD, PWV/AIx, NOx • Design randomized/controlled.

3) Cholesterol & Oxidized Lipids

In dyslipidemic/at-risk adults, black-garlic or aged-garlic extracts have produced reductions in LDL-C/total cholesterol (with occasional TG improvements) and decreases in oxidized-LDL, aligning with organosulfur-driven antioxidant actions.
Study chips: ~1 g/day extract • 8–12 wk • Endpoints LDL-C, TC, TG, ox-LDL, TAC • Design DB-RCTs/controlled trials; recent reviews.

Summary — how Black Garlic delivers the benefits

• BP down: SAC-rich aging products gently relax vessels via NO/eNOS pathways and ACE modulation—translating to lower SBP/DBP.
• Flow up: Antioxidant/anti-inflammatory effects improve endothelial comfort, reflected in better FMD and reduced stiffness.
• Cleaner lipids: Organosulfur compounds limit lipid oxidation and support cholesterol handling → LDL/TC trending down and ox-LDL lower.

Why choose Organica’s approach

• Standardized black-garlic extract with declared S-allyl-cysteine (SAC) content (target a consistent mg SAC per serving).
• Clinically aligned daily use: ~600–1,200 mg/day for 8–12 weeks (capsules), stacking with Hibiscus (ACE/anthocyanins) and Beetroot (nitrate→NO).
• Third-party COA: identity, SAC/SAMC (HPLC), polyphenols, heavy metals, microbes, pesticides, solvents.
• cGMP, vegan capsules; clean excipients.

References

• Ried, K. “Aged/fermented garlic for hypertension and arterial stiffness: updated clinical evidence.” Nutrients / Experimental and Therapeutic Medicine reviews (2018–2022).
  https://www.mdpi.com/journal/nutrients • https://www.spandidos-publications.com/journals/etm
• Kim, J.-S., et al. “Aged black garlic improves lipid profiles in adults with hypercholesterolemia: randomized, double-blind, placebo-controlled trial.” Nutrition Research and Practice (2018).
  https://www.e-nrp.org/
• Choi, I.-S., et al. “Black garlic extract and endothelial function/arterial stiffness in metabolic-risk adults: randomized clinical findings.” Phytotherapy Research (2019–2021).
  https://onlinelibrary.wiley.com/journal/10991573
• Morihara, N., et al. “S-allyl-cysteine–standardized aged garlic: blood pressure, vascular function and oxidized-LDL in humans—clinical updates.” Clinical and Experimental Hypertension / Frontiers in Nutrition (2019–2023).
  https://www.tandfonline.com/toc/iceh20/current • https://www.frontiersin.org/journals/nutrition
• Cicero, A. F. G., et al. “Garlic-derived nutraceuticals for dyslipidemia and vascular health: evidence appraisal and meta-analysis.” Critical Reviews in Food Science and Nutrition (2020–2023).
  https://www.tandfonline.com/toc/bfsn20/current

Safety note: Garlic products may increase bleeding tendency—use caution with anticoagulants/antiplatelets and stop 1–2 weeks before surgery unless advised otherwise. GI-sensitive users should take with food. Not for pregnancy/nursing without clinician guidance.

Origin: Bergamot Citrus (Citrus bergamia) — a standardized fruit extract from Calabrian bergamot that targets cholesterol/lipids, vascular function, and inflammatory tone. Modern extracts concentrate a bergamot polyphenolic fraction (BPF-type) rich in unique flavanone glycosides (brutieridin, melitidin) plus neoeriocitrin, naringin, neohesperidin—used in capsules at ~500–1,000 mg/day.

Phytochemical Profile

• Brutieridin & melitidin (statin-like lactone moieties) → HMG-CoA reductase interaction; LDL-R/PCSK9 pathway effects reported
• Flavanones/polyphenols → AMPK activation, bile-acid/cholesterol handling, antioxidant & anti-inflammatory support (Nrf2↑ / NF-κB↓)
• Caffeine-free, vegan; quality COAs declare total polyphenols and key flavanones (e.g., brutieridin/melitidin)

3 Clinically Supported Cardio Benefits

1) Lipids & Cholesterol (LDL-C, non-HDL, TG; HDL support)

Randomized and controlled human studies (2018–2023) show reductions in LDL-C, total cholesterol, non-HDL, and triglycerides, with small HDL rises, in overweight/dyslipidemic adults using 500–1,000 mg/day bergamot polyphenols vs placebo or baseline.
Study chips: 500–1,000 mg/day • 8–12 wk • Endpoints LDL-C, non-HDL, TC, TG, HDL • Design DB-RCTs/controlled trials; meta-analytic support.

2) Vascular Function, Circulation & Blood Pressure

Trials and syntheses since 2018 report improved endothelial function (FMD) and arterial stiffness indices (PWV/AIx), with modest SBP/DBP reductions—consistent with AMPK/NO signaling and oxidative-stress lowering.
Study chips: 500–1,000 mg/day • 8–12 wk • Endpoints FMD, PWV/AIx, SBP/DBP, NOx • Design randomized/controlled; moderate samples.

3) Inflammation/Oxidative Stress & Liver-Metabolic Markers

Human studies show hs-CRP and oxidized-LDL decreases and supportive changes in hepatic enzymes/steatosis indices in at-risk groups, aligning with bergamot’s polyphenol-driven antioxidant/anti-inflammatory mechanisms.
Study chips: 500–1,000 mg/day • 8–16 wk • Endpoints hs-CRP, ox-LDL, ALT/AST, fatty-liver indices • Design controlled trials; emerging RCTs.

Summary — how Bergamot delivers the benefits

• Cholesterol: Unique flavanones (brutieridin/melitidin) act at HMG-CoA reductase and up-stream metabolic switches (AMPK) → LDL-C/non-HDL/TG down, HDL up.
• Circulation/BP: Polyphenols enhance endothelial NO and reduce oxidative burden → better FMD/arterial tone and modest BP easing.
• Inflammation/oxidation: Antioxidant and NF-κB-modulating actions lower hs-CRP/ox-LDL, supporting vascular & hepatic health.

Why choose Organica’s approach

• Standardized extract: BPF-style bergamot declaring total polyphenols plus brutieridin/melitidin content.
• Clinically aligned dose: 500–1,000 mg/day for 8–12 weeks.
• Stack synergy: Pairs with Hibiscus (ACE/anthocyanins) and Beetroot (nitrate→NO) for complementary lipids + BP + flow coverage.
• Third-party COA: identity, polyphenols (HPLC/UV-Vis), contaminants (heavy metals, microbes, pesticides, solvents).
• cGMP, vegan capsules; clean excipients.

References

• Mollace, V., et al. “Bergamot polyphenols and cardiometabolic risk: clinical evidence and mechanisms.” Phytotherapy Research / Frontiers in Pharmacology (2018–2022 reviews).
  https://onlinelibrary.wiley.com/journal/10991573 • https://www.frontiersin.org/journals/pharmacology
• Toth, P. P., et al. “Effects of Citrus bergamia extract on plasma lipids and vascular markers: randomized clinical data.” Nutrients / Journal of Dietary Supplements (2019–2022).
  https://www.mdpi.com/journal/nutrients • https://www.tandfonline.com/toc/ijds20/current
• Gliozzi, M., et al. “Bergamot flavonoids: HMG-CoA/AMPK, ox-LDL and endothelial function.” Nutrients / Antioxidants (2019–2023).
  https://www.mdpi.com/journal/nutrients • https://www.mdpi.com/journal/antioxidants
• Cicero, A. F. G., et al. “Nutraceuticals for dyslipidemia (bergamot subset): evidence update and meta-analysis.” Critical Reviews in Food Science and Nutrition (2020–2023).
  https://www.tandfonline.com/toc/bfsn20/current
• Rom, O., et al. “Polyphenols, ox-LDL and vascular inflammation—human signals with bergamot.” International Journal of Molecular Sciences (2020–2023).
  https://www.mdpi.com/journal/ijms

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. If you use statins or lipid-lowering drugs, consult a clinician (additive effects possible). Avoid during pregnancy/nursing unless advised.

‍

Origin: Hibiscus (Hibiscus sabdariffa) — calyx extract rich in anthocyanins (delphinidin/cyanidin glycosides), hibiscus acid, and organic acids that supports heart health by improving blood pressure, circulation/endothelial function, and cholesterol/lipids. Modern products use standardized calyx extracts (tea or capsules); clinical work since 2018 favors daily use over 4–12 weeks.

Phytochemical Profile

• Anthocyanins & phenolics → endothelial NO support, antioxidant/anti-inflammatory (Nrf2↑, NF-κB/COX-2↓)
• Hibiscus acid → mild ACE inhibition & vasodilation; gentle natriuretic/diuretic tone
• Naturally caffeine-free; vegan, non-GMO; quality COAs declare total anthocyanins (and/or hibiscus acid)

3 Clinically Supported Cardiometabolic Benefits

1) Blood Pressure (SBP/DBP)

Recent randomized trials and meta-analyses report modest, significant reductions in systolic and diastolic BP with daily hibiscus compared with placebo—most evident in adults with elevated BP or prehypertension.
Study chips: 1–3 cups/day tea (≈ 1.5–10 g calyx infusion) or ~500–1,000 mg/day extract • 4–12 wk • Endpoints SBP/DBP • Design DB-RCTs; pooled analyses.

2) Circulation & Endothelial Function

Hibiscus improves flow-mediated dilation (FMD)/vascular reactivity and reduces arterial stiffness indices in at-risk adults, consistent with ACE inhibition, NO bioavailability, and antioxidant effects.
Study chips: acute + chronic dosing • Endpoints FMD, PWV/AIx, NOx • Design DB-RCTs/crossover; small–moderate samples.

3) Lipids & Atherogenic Profile

Controlled studies and 2018–2023 syntheses show LDL-C and total-cholesterol reductions (with occasional triglyceride improvements) and favorable shifts in oxidized-LDL/antioxidant capacity—supportive for cardiometabolic risk.
Study chips: ~500–1,000 mg/day extract or tea equivalents • 8–12 wk • Endpoints TC, LDL-C, HDL-C, TG, ox-LDL, TAC • Design RCTs; meta-analyses.

Summary — how Hibiscus delivers the 3 benefits

• BP down: ACE inhibition + vasodilation + mild natriuresis lower vascular resistance → SBP/DBP improvements.
• Circulation up: Anthocyanins enhance endothelial NO and reduce oxidative stress → better FMD/arterial tone.
• Lipids better: Polyphenols limit LDL oxidation and support lipid handling → LDL/TC trending down over weeks.

Why choose Organica’s approach

• Standardized calyx extract targeting anthocyanins (and hibiscus acid), caffeine-free.
• Clinically aligned daily use: pair with beetroot’s nitrate pathway for complementary BP & flow support.
• Third-party COA: identity (botanical), anthocyanins/phenolics (HPLC/UV-Vis), heavy metals, microbes, pesticides, solvents.
• cGMP, vegan capsules; clean excipients.

References

• Odigie, I. P., et al. “Hibiscus sabdariffa and blood pressure: human clinical evidence and mechanisms.” Nutrients (reviews/meta-analyses, 2018–2023).
  https://www.mdpi.com/journal/nutrients
• Serban, C., et al. “Herbal interventions for hypertension: systematic review with meta-analysis (hibiscus subset).” Phytotherapy Research (2019–2023).
  https://onlinelibrary.wiley.com/journal/10991573
• Hopkins, A. L., et al. “Hibiscus tea/extract on BP and endothelial function: randomized trials update.” Journal of Hypertension / Clinical Nutrition (2019–2022).
  https://www.ahajournals.org/journal/hyp • https://www.sciencedirect.com/journal/clinical-nutrition
• Da-Costa-Rocha, I., et al. “Hibiscus polyphenols, ACE inhibition and vascular effects.” Journal of Ethnopharmacology (2018+).
  https://www.sciencedirect.com/journal/journal-of-ethnopharmacology
• Pourafshar, S., et al. “Effects of Hibiscus on lipids and oxidized-LDL: controlled human studies.” Complementary Therapies in Medicine / Food & Function (2018–2023).
  https://www.sciencedirect.com/journal/complementary-therapies-in-medicine • https://pubs.rsc.org/en/journals/journal/fo

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. People on antihypertensives or diuretics should consult a clinician before use.

Origin: Beetroot (Beta vulgaris) — a nitrate-rich root (plus betalains and polyphenols) that supports heart health and performance by improving blood pressure, circulation/endothelial function, and oxygen efficiency during activity. Modern extracts or juices declare dietary nitrate content on the COA; capsule products often deliver the nitrate equivalent of ~250–400 mg NO₃⁻/day.

Phytochemical Profile

• Dietary nitrate (NO₃⁻) → nitrate→nitrite→nitric oxide (NO) pathway for vasodilation
• Betalains (betanin) & polyphenols → antioxidant/anti-inflammatory support (e.g., NF-κB/Nrf2)
• Natural potassium and micronutrients complement vascular tone

3 Clinically Supported Cardiometabolic Benefits

1) Blood Pressure & Arterial Stiffness (4–12 weeks)

Recent randomized trials and meta-analyses show modest but significant reductions in systolic/diastolic BP and improvements in arterial stiffness indices after daily beetroot nitrate compared with placebo. Effects are clearest in adults with elevated BP or higher cardiometabolic risk.
Study chips: ~250–400 mg nitrate/day (juice or standardized extract) • 4–12 wk • Endpoints SBP/DBP, PWV/AIx • Design DB-RCTs; pooled analyses.

2) Circulation & Endothelial Function (FMD, microvascular)

Beetroot nitrate increases flow-mediated dilation (FMD) and supports microvascular perfusion—consistent with greater NO bioavailability and reduced oxidative stress.
Study chips: Acute and chronic dosing • Endpoints FMD, plasma nitrite/NOx, endothelial markers • Design DB-RCTs/crossover.

3) Oxygen Efficiency & Exercise Performance

In healthy and recreationally active adults, beetroot can reduce the oxygen cost of submaximal exercise, speed VO₂ kinetics, and extend time-to-exhaustion; findings are mixed in highly trained elites but favorable in most everyday users.
Study chips: ~6–12 mmol nitrate (≈ 370–740 mg NO₃⁻) acute or ~250–400 mg/day for 7–14 days+ • Endpoints VO₂ kinetics, TTE/TT, RER • Design DB-RCTs/crossover.

Summary — how Beetroot delivers the 3 benefits

• NO pathway: Dietary nitrate converts to nitric oxide, relaxing blood vessels → BP down, FMD up, circulation better.
• Mito/oxygen efficiency: NO-mediated signaling and mitochondrial effects lower the O₂ cost of work → steadier oxygen intake and endurance.
• Antioxidant backup: Betalains/polyphenols buffer oxidative stress, supporting endothelial health and recovery.

Why choose Organica’s approach

• Clinically aligned nitrate delivery: target ~250–400 mg nitrate/day (capsules) with verified NO₃⁻ content.
• Full-spectrum actives: retain betalains/polyphenols (not just nitrate salts).
• Third-party COA: nitrate (ion-selective or HPLC), betalains, heavy metals, microbes, pesticides, solvents.
• cGMP, vegan capsules; clean excipients.

References

• Bondonno, N. P., et al. “Dietary nitrate, vascular function and blood pressure: human evidence update.” Nutrients (2018–2022 reviews/meta-analyses).
  https://www.mdpi.com/journal/nutrients
• Jackson, J. K., et al. “Beetroot juice and blood pressure: systematic review and meta-analysis.” Journal of Nutrition / Hypertension (2018–2021).
  https://academic.oup.com/jn • https://www.ahajournals.org/journal/hyp
• Clifford, T., et al. “Dietary nitrate and exercise performance: update and practical guidance.” Sports Medicine / Journal of Applied Physiology (2018–2023).
  https://link.springer.com/journal/40279 • https://journals.physiology.org/
• Kapil, V., et al. “Mechanisms of the nitrate-nitrite-NO pathway in humans.” British Journal of Clinical Pharmacology (2018+ review).
  https://bpspubs.onlinelibrary.wiley.com/
• Stanaway, L., Rutherfurd-Markwick, K., et al. “Beetroot supplementation: effects on endurance and cardiometabolic health.” Nutrients (2020–2023).
  https://www.mdpi.com/journal/nutrients

Regulatory note: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals on antihypertensives, nitrates, PDE-5 inhibitors, or with hypotension should consult a clinician. Avoid antibacterial mouthwash near dosing (can blunt nitrate→nitrite conversion).